POM-V Prescription Required Companion Animal

Soluclin 25 mg/ml Oral Solution for Cats and Dogs

Active ingredient: Clindamycin

Form

Liquid

Species

Cats Dogs

Manufacturer

CP Pharma Handelsgesellschaft mbH

VMD MA No.

20916/3009

What it's used for

AN: 00053/2025 & 00069/2025 Dogs: • infections caused by or associated with clindamycin-susceptible species of Staphylococcus spp., Streptococcus spp., spp...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clindamycin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Soluclin 25 mg/ml Oral Solution for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

AN: 00053/2025 & 00069/2025
Dogs:
•
infections caused by or associated with clindamycin-susceptible species of
Staphylococcus spp., Streptococcus spp., spp.,
necrophorum, Clostridium perfringens.
•
treatment of infections of the gingival and periodontal tissues.
•Staphylococcus aureus.

Recommended dose:
Cats:
Infected wounds, abscesses: 11 mg of clindamycin per kg of body weight (i.e.
approximately 0.5 mL of product / kg bw) per 24 hours or 5.5 mg / kg (i.e.
approximately 0.25 mL of product / kg bw) per 12 hours for 7 to 10 days.
The treatment should be stopped if no therapeutic effect is observed after 4 days.
Dogs:
•
clindamycin per kg of bodyweight (i.e. approximately 0.5 mL of product / kg bw)
per 24 hours or 5.5 mg / kg (i.e. approximately 0.25 mL of product / kg bw) per
12 hours for 7 to 10 days.
The treatment should be stopped if no therapeutic effect is observed after 4
days.
•
weight (i.e. approximately 0.5 mL of product / kg bw) per 12 hours for a period
of 28 days minimum. The treatment should be discontinued if no therapeutic
effect is observed in the first 14 days.
To ensure administration of a correct dose, body weight should be determined as
accurately

as possible.
A 3 ml graduated syringe is provided to facilitate the administration of the veterinary

medicinal product.
The solution can be administered directly into the mouth of the

animal or added to
a small quantity of food.
Instructions: remove the cap from the bottle, insert the syringe tip into the adapter of the
bottle, invert the bottle to draw up the required dose, return the bottle to an upright
position and remove the syringe from the bottle.

Do not use in hamsters, guinea pigs, rabbits, chinchillas, horses or ruminants
because clindamycin ingestion by these species may cause severe gastrointestinal
disorders.
Do not use in cases of hypersensitivity to either clindamycin or lincomycin, or to any
of the excipients.

Cats and dogs:
Very rare
(<1 animal / 10 000 animals
treated, including isolated
reports):
Vomiting and/or diarrhoea
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the section ‘Contact details’ of the package leaflet.

Cross-resistance has been shown between clindamycin and different antimicrobials
belonging to lincosamides and macrolides classes (including erythromycin).
Use of clindamycin should be carefully considered when susceptibility testing has
shown resistance to lincosamides and macrolides because its effectiveness may be
reduced.
An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG
category) should be used for first line treatment where susceptibility testing suggests
the likely efficacy of this approach.

Special precautions for safe use in the target species:
Use of the product should be based on identification and susceptibility testing of the
target pathogen(s) including the D-zone test.
If this is not possible, therapy should be based on epidemiological information and
knowledge of susceptibility of the target pathogens at local/regional level.
Use of the product should be in accordance with official, national and regional
antimicrobial policies.
Clindamycin is likely to favour the proliferation of non-susceptible organisms such as
resistant

Clostridia
corrective measures

should be taken based on clinical observations.
In case of administration of high doses of clindamycin or during prolonged therapy
of one

month or greater, tests for liver and renal functions and blood counts should
be performed

periodically.
In dogs and cats with kidney problems and/or liver problems, accompanied by severe

metabolic aberrations, the dose to be administered should be carefully determined
and their

condition should be monitored by performing appropriate blood tests during
treatment.
The use of the product is not recommended in neonates.
AN: 00053/2025 & 00069/2025
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Wash hands carefully after use.
This veterinary medicinal product may cause hypersensitivity (allergic reaction).
People with known hypersensitivity to lincosamides (clindamycin and lincomycin)
should avoid contact with the veterinary medicinal product.
Care should be taken to avoid accidental ingestion as this may result in gastro-
intestinal effects such as abdominal pain and diarrhoea.
In case of accidental ingestion, particularly by a child, or allergic reaction seek
medical advice immediately and show the package leaflet or the label to the
physician.
In order to limit the spread of resistant bacteria, general hygiene precautions should
be implemented. Washing hands with soap and water are especially recommended
when handling the treated animals, their waste and their bedding material.
Special precautions for the protection of the environment:
Not applicable.

-Aluminium salts and hydroxides, kaolin and Aluminium-Magnesium-Silicate complex
may reduce the gastrointestinal absorption of lincosamides. Products containing
these substances should be administered at least 2 hours before clindamycin.
-Cyclosporin: clindamycin may reduce levels of this immunosuppressive drug with a
risk of lack of activity.
AN: 00053/2025 & 00069/2025
-Neuro-muscular blocking agents: clindamycin possesses intrinsic neuromuscular
blocking activity and should be used cautiously with other neuromuscular blocking
agents (curares). Clindamycin may increase neuromuscular blockade.
-Do not use clindamycin simultaneously with chloramphenicol or macrolides as they
both target the ribosome 50S subunit and antagonist effects may develop.
-When using clindamycin and aminoglycosides (e.g. gentamicin) simultaneously, the
risk of adverse interactions (acute renal failure) cannot be excluded.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.